About the Company
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZNTL News
Zentalis Pharmaceuticals Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Earnings Estimate Revisions for Zentalis Pharmaceuticals, Inc. This company is expected to earn -$4.49 per share for the fiscal year ending December 2023, which represents a year-over-year change ...
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price
The projected fair value for Zentalis Pharmaceuticals is US$ ... are going to estimate the intrinsic value of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by estimating the company's future cash ...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Corporate Updates Anticipated Upcoming Milestones Full Year 2023 Financial Results About Azenosertib Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and ...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental ...
Loading the latest forecasts...